Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 849Carcinoma, Non-Small-Cell Lung 551Neoplasms 509Prostatic Neoplasms 501Lung Neoplasms 313Colorectal Neoplasms 307Multiple Myeloma 289Neoplasm Metastasis 251Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 209Pancreatic Neoplasms 206Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 164Stomach Neoplasms 162Recurrence 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 151Glioblastoma 147Uterine Cervical Neoplasms 144Head and Neck Neoplasms 141Lymphoma, Non-Hodgkin 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 114Lymphoma, Follicular 112

Interventions

enzalutamide 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Hormone Sensitive Prostate Cancer × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡